Side-by-side · Research reference
P21vsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BHuman-MechanisticAUTO-DRAFTED12/40 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
P21
Thymalin
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Thymalin
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Russian clinical + in vitroKhavinson 2002
Duration
Not specified
5–10 day cycles, 1–2× per year
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Reconstitution
—
Saline or bacteriostatic water
Timing
—
Morning preferred
Half-life
—
Hours (estimated)
04Side Effects & Safety
Parameter
P21
Thymalin
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Injection site reaction
—
Mild erythema at IM site
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
P21
- ·Use in humans not validated
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
P21
Thymalin
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
—
Morning preferred during cycle.
4. Storage
—
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
—
23–25G, 25–38 mm IM needle.
06Stack Synergy
P21
— no documented stacks
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation